The study was approved once. Every repurposed version is a new claim

SwishX Team·9 min read
Contents
  1. Introduction
  2. Where does repurposing sit in modular content?
  3. Why is repurposing where compliance risk enters?
  4. What can travel unchanged, and what must be rewritten?
  5. What checks should every derivative get?
  6. Worked example: one Brevanta study, five assets
  7. How do you keep derivatives tied to the source when the label changes?
  8. Where SwishX fits
  9. Frequently asked questions

Turning one pivotal study into an email, a detail aid, a video, a social ad and a patient leaflet is where most compliance risk enters. What can travel unchanged, what must be rewritten, and the checks every derivative needs.

Content repurposing in pharma means taking one piece of evidence, such as a pivotal trial publication, a label update, a congress readout or a real-world evidence study, and turning it into many channel-ready assets: an HCP email, a detail aid page, a short video, a social ad, a patient leaflet, a web page. It is the second half of modular content. The claims library holds the approved claims, and repurposing is what a team does with them. It is also where most compliance risk enters.

The reason is that FDA judges a communication by the overall impression it creates for its own audience. A claim approved in a twelve-page HCP detail aid can become misleading in a consumer leaflet or a short social post without a single word changing. This article covers what can travel between assets unchanged, what has to be rewritten per audience, the checks to run on each derivative, a worked example on a fictional brand, and how to keep derivatives tied to their source so a label change reaches all of them. It reflects US rules as of November 2026 and is not legal advice.

Where does repurposing sit in modular content?

Modular content has two halves. The first is decomposition: breaking approved evidence into components, such as a claim with its reference, a statistic, a visual or the safety information, and combining them into pre-approved modules. The second is recomposition: assembling those modules into finished assets for a specific channel and audience. Many programs treat the second half as mechanical, and it is not.

A trial publication reports endpoints, subgroups, safety tables and limitations. A detail aid page holds a handful of those; a social ad holds one line. Every repurposing decision is a selection, and FDA's advertising regulation polices selection. Among the ways 21 CFR 202.1(e)(6) says an advertisement can be false or misleading are presenting information from a study in a way that implies it represents larger or more general experience than it does, and using a quote or paraphrase out of context.

So the unit worth tracking is not the asset. It is the pairing of a claim with a context: the audience, the format, the length and the content around it. Change any one of the four and you have something new to review, even when the words match exactly.

Why is repurposing where compliance risk enters?

Audience shift is the first trap. Hazard ratios and relative risk reductions read correctly to a physician and badly to a patient. FDA's guidance on presenting quantitative efficacy and risk information in DTC promotion, final since June 2023 and revised in December 2023, recommends absolute frequencies or percentages, control-group figures where there was a control group, and absolute numbers shown prominently beside any relative figure. An HCP statistic lifted unchanged into consumer material can miss all three.

Truncation is the second. Short formats drop qualifiers first: the approved population, a limitation of use, the comparator, the timepoint. Under 21 CFR 202.1(e)(5)(iii), an advertisement fails if it does not reveal facts material in light of its own representations. FDA's 2014 draft guidance on platforms with character space limits, still a draft as of November 2026, says each message carrying benefit information should also carry at least the most serious risks, plus a link to fuller risk information. If that cannot fit, the firm should reconsider the platform for that message.

The third is an endpoint promoted on its own: a secondary endpoint, one component of a composite or a subgroup result lifted from a results table into a headline. FDA's June 2018 final guidance on communications consistent with the FDA-required labeling uses this case. Analyses of composite components that were not adequately powered, or did not control type 1 error, do not support efficacy conclusions, and showing p-values implies rigor that is not there. Its suggested route is a descriptive presentation, without p-values, with the limitation stated.

The fourth is data that is not in the label, which mostly arrives with congress readouts and real-world evidence. The 2018 guidance sets three factors: whether the information conflicts with the labeling's conditions of use (indication, population, limitations and directions for use, dosing), whether it increases the potential for harm, and whether the labeling's directions allow safe and effective use under the conditions suggested. Failing any one means the communication is not consistent with the labeling.

The fifth is context lost even when the data is consistent. The guidance asks for data that is scientifically appropriate and statistically sound, clear and prominent disclosure of material design facts and unfavorable findings, and related data from the labeling shown alongside for context. Those sentences are cut first when a layout gets tight.

What can travel unchanged, and what must be rewritten?

Some things travel verbatim, never retyped: the approved claim wording within the audience it was approved for, its reference, the indication statement, a boxed warning, the brand name paired with the established name, any qualifier bound to the claim, and the ISI module for that audience. Anything stated in the label, or approved as a fixed companion to a claim, moves as a block.

Other things must be rewritten for each audience: how numbers are expressed, the terminology, the way risk is described, the call to action and the selection of claims. Some HCP claims, such as comparative data, may not belong in patient material at all. Rewriting here does not mean paraphrasing an approved claim freely. It means using an approved patient variant from the library, or drafting a new claim and sending it through full review.

Some things should not travel into a given format at all. If the qualifier that keeps a claim truthful does not fit, the claim does not go. An exploratory analysis stripped of its limitation is not a shorter finding. It is a different, misleading one.

What checks should every derivative get?

Run seven checks on every derivative. Source match: every number and phrase traces to an approved claim, its reference and the current label version. Audience fit: the claim is approved for this audience, and consumer numbers follow the DTC quantitative guidance. Qualifiers present: population, comparator, timepoint, endpoint type and any material limitation.

Endpoint hierarchy: the primary endpoint reads as primary, secondary and subgroup results are labelled as such, and no p-value appears on an analysis that was not controlled for multiplicity. Label consistency: anything not in the prescribing information passes all three factors from the 2018 guidance. Balance in this format: risk keeps fair balance at this size, length and position, and character-limited posts carry their most serious risks in the same message. Net impression: the headline, image and music say nothing the claim does not.

A lighter review path for reuse is reasonable only when a derivative passes all seven with no new pairing of claim and context. A new audience, a shorter format or a new combination of claims is a new context and gets read as one.

Worked example: one Brevanta study, five assets

Brevanta is a fictional once-daily oral treatment for adults with moderate to severe plaque psoriasis, used only as an illustration. The source is the publication of its pivotal phase 3 trial: placebo-controlled, a primary endpoint at week 16, two key secondary endpoints, a prespecified subgroup analysis in older adults and an exploratory quality-of-life analysis.

HCP approved email: the primary endpoint claim verbatim from the library, with comparator, timepoint and population, plus one key secondary endpoint labelled as secondary. Safety information sits in the body, and the subject line makes no claim the body does not balance. Detail aid page: room for the primary and both secondaries, a study design box and safety drawn from the label. The quality-of-life analysis either stays out or appears descriptively, without p-values and marked exploratory, and MLR makes that call.

Short HCP video: one claim, a readable design footnote, and risk as prominent as the benefit. Consumer social ad: the HCP efficacy wording cannot travel. A benefit claim means the approved patient variant, the indication, the most serious risks and a link, in one post. If that does not fit, the draft guidance points to another platform. Patient leaflet: the approved patient wording, efficacy in absolute terms with the placebo figure beside it, risk in plain language, and no subgroup data.

One thing deliberately did not travel. The older-adult subgroup result stays in the detail aid, next to its design context, and nowhere else. Each of the five assets records the claim IDs, label version and ISI version it was built from.

How do you keep derivatives tied to the source when the label changes?

Treat repurposing as a family tree: source evidence, then claims, then modules, then assets. Every derivative records its parents: the source study, the claim and variant IDs, the label version, the ISI version, the audience and the channel. Approved labeling has to be updated when new information makes it inaccurate, false or misleading (21 CFR 201.56(a)(2)), and when it is, the tree turns a search into a list.

Walk it from the changed label section to the affected claims, then to every module and asset using them. The label change playbook covers what to withdraw, what to revise and how to resubmit. You can only cascade a change through derivatives you can find.

Two habits break the tree. The first is deriving from another derivative, so the social ad is cut from the email rather than built from the library. It inherits the email's compromises and loses the source link. The second is keeping assets built on a congress readout after the full publication supersedes it. Derive from the library every time, and retire the children when their source is superseded.

Where SwishX fits

Magic Studio is built for the second half of modular content. Each brand keeps one Brand Dossier with its claims, evidence, ISI, fair balance language, audience definitions and channel requirements, and the studios (Video, Visual Aids, Ads, Approved Email and Web) write from it, so a claim does not drift between a video script, a visual aid and an email. Every claim is cited to its source and checked against the label for its market, and fair balance and safety information are placed in the asset as it is made.

Anyone can ask an asset where a line came from, which is the question every derivative check starts with. Finished work goes into the MLR queue and on into Veeva PromoMats with every claim and its reference attached, and your reviewers still decide what each audience and channel can carry.

Frequently asked questions

What is content repurposing in pharma?

It is turning one piece of evidence, such as a pivotal study, a label update or a congress readout, into many channel-ready assets for HCPs and patients. Each asset is a new pairing of claim and context, so each needs its own check.

Can an HCP claim be reused in patient materials?

Usually not unchanged. Consumer materials need plain language and, under FDA's DTC quantitative information guidance, absolute numbers with control-group figures, so the route is an approved patient variant or a new claim through full review.

Can you promote study data that is not in the prescribing information?

Possibly, if it is consistent with the FDA-required labeling under the three factors in FDA's 2018 final guidance and is presented with its material context and limitations. Data about a different indication or population fails that test.

Do repurposed assets need MLR review again?

Yes, though the depth can vary. Many teams agree a lighter path for approved modules reused in an approved context, while a new audience, a shorter format or a new combination of claims goes through full review.

How do you repurpose pharma content for social media with character limits?

FDA's 2014 draft guidance says each post with benefit information should also include at least the most serious risks and a link to fuller risk information. If both cannot fit, the draft suggests that platform may not suit the message.

Filed underPlatform

Keep reading

All articles

Want to see Magic Studio on your brand?

Video, visual aids, ads, approved email and web, made from your approved claims and ready for MLR review.